Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Analysis: Coding and Claim Submission Guidelines
Genetic testing for cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is typically performed to screen adults with a positive family history of CF. Effective for dates of service on and after January 1, 2013, CGS has determined that CFTR gene testing to identify parents at risk is not a Medicare benefit and is considered a statutorily excluded test. In addition to single disease testing, CGS will also deny panels of tests that include the CFTR gene test for CF as statutorily excluded tests.
The following tests have been identified as non-covered:
| Test | CPT Code |
|---|---|
| CF DNA ANALYSIS - FETUS | 81220 |
| CYSTIC FIBROSIS MUTATION PANEL | 81220 |
| Cystic Fibrosis Cis-Trans (CFTR) R117H & 5T Mutations | 81220 |
| Cystic Fibrosis (CFTR) 32 Mutations | 81220 |
| Cystic Fibrosis (CFTR) 32 Mutations, Atypical | 81220 |
| Cystic Fibrosis (CFTR) 32 Mutations, Fetal | 81220 |
| Cystic Fibrosis (CFTR) 5T Mutation | 81220 |
| Cystic Fibrosis Profile | 81220 |
| CYSTIC FIBROSIS MUTATION PANEL | 81220 |
| Cystic Fibrosis Mutation Screen | 81220 |
| CYSTIC FIBROSIS 23 MUTATION ANALYSIS | 81220 |
| Cystic Fibrosis 32 Mutation Study, Non-Blood | 81220 |
| Cystic Fibrosis (CFTR) 32 Mutations | 81220 |
| Cystic Fibrosis (CFTR) 5T Mutation | 81479 |
| Molecular Cystic Fibrosis Mutation Screen | 81220 |
| CYSTIC FIBROSIS CARRIER SCREENING | 81220 |
| Cystic Fibrosis Targeted Mutation Panel | 81220 |
| Cystic Fibrosis Genotype 23 MUTATIONS | 81220 |
| CYSTIC FIBROSIS DNA | 81220 |
| C. FIBROSIS RARE MUTATION | 81221 |
| CYSTIC FIBROSIS 2 EXON | 81221 |
| CYSTIC FIBROSIS D1152H | 81221 |
| Cystic Fibrosis Known Familial Mutation One exon | 81221 |
| CFTR Gene, Known Mutation | 81221 |
| Cystic Fibrosis Diagnostic Sequencing Assay (One Exon) | 81221 |
| Cystic Fibrosis Diagnostic Sequencing Assay (Two Exons) | 81221 |
| Cystic Fibrosis (CFTR) 3199del6 Mutation | 81222 |
| CYSTIC FIBROSIS CFTR GENE | 81222 |
| Cystic Fibrosis (CFTR) Deletion/Duplication | 81222 |
| CFTR Gene, Known Mutation | 81222 |
| CFTR Gene, Full Gene Analysis | 81222 |
| CFTR Deletion/Duplication Analysis by MLPA, blood | 81222 |
| CYSTIC FIBROSIS RARE MUT | 81223 |
| Cystic Fibrosis Full Gene Sequencing | 81223 |
| Cystic Fibrosis (CFTR) Sequencing | 81223 |
| CFTR Gene, Full Gene Analysis | 81223 |
| Cystic Fibrosis Diagnostic Sequencing Assay | 81223 |
| Cystic Fibrosis Diagnostic Sequencing Assay (Two Exons) | 81223 |
| Cystic Fibrosis CFTR Full Gene Sequencing | 81223 |
| Cystic Fibrosis (CFTR) 5T Mutation | 81224 |
| CFTR INTRON 8 POLY-T ANALYSIS | 81224 |
| CF Poly-T Analysis | 81224 |
Health care providers are not required to submit claims to Medicare for statutorily non-covered services; however, you may choose to submit claims (e.g., at the patient's request). Claims for CFTR must include:
- Appropriate CPT code for the test (see above table)
- HCPCS modifier GY (statutorily non-covered service)
- The appropriate ICD-9-CM code(s)
- The name of the test:
- Electronic claims: Loop 2400, NTE02, or SV101-7 field
- Paper claims: Block 19
Reference:
- Definition of "reasonable and medically necessary": Social Security Act, section 1862(a)(1)(A)
- Exception to mandatory claim submission for "categorically excluded services": CMS MLN Matters article SE0908, "Mandatory Claims Submission and Its Enforcement"

- Guidance on issuing Advance Beneficiary Notices of Noncoverage (ABNs) on a voluntary basis for statutorily excluded services: CMS Beneficiary Notices Initiative Web page – Fee-For-Service (FFS) ABN


